Elutia Inc
ELUT
查看详细走势图
0.586USD
+0.044+8.03%
收盘 12/19, 16:00（美东）报价延迟15分钟
24.95M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.03%
5天
-15.99%
1月
-4.67%
6月
-67.61%
今年开始到现在
-84.32%
1年
-87.89%
查看详细走势图
TradingKey Elutia Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Elutia Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在药品行业排名89/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.50。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Elutia Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
3.500
目标均价
+416.22%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Elutia Inc亮点
亮点风险
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
业绩增长期
公司处于发展阶段，最新年度总收入24.38M美元
利润高增长
公司净利润处于行业前列，最新年度总收入24.38M美元
估值高估
公司最新PE估值-0.94，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值61.99K
Elutia Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Elutia Inc简介
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
公司代码ELUT
公司Elutia Inc
CEOMills (C. Randal)
网址https://elutia.com/
常见问题
Elutia Inc(ELUT)的当前股价是多少？
Elutia Inc(ELUT)的当前股价是 0.586。
Elutia Inc的股票代码是什么？
Elutia Inc的股票代码是ELUT。
Elutia Inc股票的52周最高点是多少？
Elutia Inc股票的52周最高点是4.840。
Elutia Inc股票的52周最低点是多少？
Elutia Inc股票的52周最低点是0.500。
Elutia Inc的市值是多少？
Elutia Inc的市值是24.95M。
Elutia Inc的净利润是多少？
Elutia Inc的净利润为-53.95M。
现在Elutia Inc(ELUT)的股票是买入、持有还是卖出？
根据分析师评级，Elutia Inc(ELUT)的总体评级为买入，目标价格为3.500。
Elutia Inc(ELUT)股票的每股收益（EPS TTM）是多少
Elutia Inc(ELUT)股票的每股收益（EPS TTM）是-0.626。
相关品种
